source
- Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipelineEli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
- Addiction Society Issues First Guidance on Managing Medetomidine WithdrawalThe American Society of Addiction Medicine (ASAM) has published its first national guidance for clinicians on how to identify and treat patients experiencing withdrawal from medetomidine, a sedativ…